Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple kombinasjon terapi) som et tillegg til diett og trening hos pasienter ikke kontrollert på deres maksimal tolerert dose av metformin og en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Den europeiske union - norsk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple kombinasjon terapi) som et tillegg til diett og trening hos pasienter ikke kontrollert på deres maksimal tolerert dose av metformin og en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Norge - norsk - Statens legemiddelverk

orifarm healthcare a/s - magnesiumlaktatdihydrat / magnesiumsitratpentahydrat - tyggetablett

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Norge - norsk - Statens legemiddelverk

laboratoire aguettant - suksametoniumkloriddihydrat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 10 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab  - metformin hydrochloride, saxagliptin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze er angitt som et supplement til kosthold og mosjon for å forbedre glykemisk kontroll hos voksne pasienter over 18 år og eldre med type 2 diabetes mellitus mangelfullt kontrollert på sin maksimalt tolerert dose av metformin alene eller de allerede behandlet med en kombinasjon av saxagliptin og metformin som separate tabletter. komboglyze er også indisert i kombinasjon med insulin (jeg. triple kombinasjon terapi) som et tillegg til diett og trening for å bedre glykemisk kontroll hos voksne pasienter i alderen 18 år og eldre med type-2 diabetes mellitus når insulin og metformin alene ikke gir tilstrekkelig glykemisk kontroll.

Norge - norsk - Statens legemiddelverk

teva b.v. - bupropionhydroklorid - tablett med modifisert frisetting - 150 mg

Norge - norsk - Statens legemiddelverk

teva b.v. - bupropionhydroklorid - tablett med modifisert frisetting - 300 mg

Norge - norsk - Statens legemiddelverk

baxter medical ab - natriumklorid / kaliumklorid / magnesiumkloridheksahydrat / natriumacetattrihydrat / natriumglukonat - infusjonsvæske, oppløsning - 5.26 g/ l / 0.37 g/ l / 0.3 g/ l / 3.68 g/ l / 5.02 g/ l